As per the agreement, ThromboGenics will receive an upfront payment of €75m and also a further €90m in potential near-term milestone payments.
Additional milestones bring the potential total of upfronts and milestones to €375m, the agreement specifies.
ThromboGenics will receive royalties on net sales of ocriplasmin that are commensurate with a product that has completed Phase III development and that has been filed for the approval.
ThromboGenics will have a strategic operational role in the commercialization of ocriplasmin in five European markets.
The companies will work together, and share the costs, to further develop new applications of the product that will be introduced in their respective territories.
ThromboGenics plans to build its commercial and medical organization to support the product’s anticipated launch within the next 12 months.
ThromboGenics CEO Patrik De Haes said the collaborative deal with Alcon to commercialize ocriplasmin outside of the US is a major milestone for ThromboGenics.